Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway
- Department of Circulation and Medical Imaging
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy
- Normal electrocardiogram (ECG)
- Hemoglobin: male 13.4 - 17.0 g/dL, female 11,7- 15.3 g/dL
- Creatinine: male 60- 105 micromol/L female 45- 90 micromol/L
- ASAT: male 15- 45 U/L, female 15- 35 U/L
- ALAT: male 10- 70 U/L female 10- 45 U/L
- Gamma GT: male 10- 80 U/L female 10- 45 U/L
- HCG normal under 3 ye/L
- Fertile women must use safe contraception and have a negative serum HCG at inclusion
Exclusion Criteria:
- Taking any medications including herbal medicines the last week prior to first treatment visit
- History of drug abuse
- History of prior drug allergy
- Having any local nasal disease or nasal surgery or recent cold for the last week
- Pregnancy
- Fertile women not using high efficacy contraceptives (Oral contraceptives, Patch (Evra), Implants, Vaginal ring, Hormonal IUD, Copper IUD, Sterilization) throughout the study period until their last visit.
- Lactating women
- Any reason why, in the opinion of the investigator, the patient should not participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: nasal naloxone
8 and 16 mg/ml, comparator 1 mg/ml.
Three daily occasions with at least 3 days washout between treatment (min 8 days).
|
one puff in one nostril with the subject is lying down
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
bioavailability of naloxone
Time Frame: 2 weeks
|
A LCMSMS method for determination of Naloxone in serum was developed using acetonitrile protein precipitation.
Naloxone D5 was used as internal standard and quantitative determination was done by using Sciex Analyst version 1.5.
The method is fully validated by assessing linearity, accuracy, precision, sensitivity, specificity/selectivity, in process and storage stability, dilution integrity and assay ruggedness according to Dadgar (1995) and Shah (1991).
The method was found linear, accurate and precise across the dynamic range of 0.05 to 45 ng/ml.
Limit of quantification (LOQ) was 0.05ng/ml with CV = 12.7% and inaccuracy < 7.8% (n = 17).
Quality Controls (QC) in middle (n=18) and upper (n=18) calibration range had CV < 4.2% and inaccuracy <8.2 %
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum serum concentration (Cmax)
Time Frame: 2 weeks
|
2 weeks
|
|
|
Time to maximum serum concentration (Tmax)
Time Frame: 2 weeks
|
2 weeks
|
|
|
adverse events
Time Frame: 2 weeks
|
will be reported from the start of the first session to the follow-up visit.
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OPI-13-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.